SCHEMBL14730205

SCHEMBL14730205

CN(C(=O)c1cnc(N2C[C@H](NC(=O)OC(C)(C)C)[C@@H](c3cc(F)ccc3F)C2)nc1)C1CCN(c2nc(C(F)F)no2)CC1

nearest known ligand 0.34

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
NTRK1 P04629 3/20 0.34
VNN1 O95497 1/20 0.34
NR1H2 P55055 3/20 0.33
NR1H3 Q13133 2/20 0.33
BRAF P15056 2/20 0.33
EIF2AK4 Q9P2K8 1/20 0.32
CCR5 P51681 1/20 0.32
ACKR3 P25106 1/20 0.32
KDM4D Q6B0I6 1/20 0.31
MAPT P10636 1/20 0.31
HDAC4 P56524 1/20 0.31
HDAC6 Q9UBN7 1/20 0.31
HTR2A P28223 1/20 0.31
DRD3 P35462 1/20 0.31
GPR119 Q8TDV5 1/20 0.31
MEN1 O00255 1/20 0.31
KMT2A Q03164 1/20 0.31
CYP46A1 Q9Y6A2 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14730202 0.91 NTRK1 (0.35) NTRK1VNN1NR1H2NR1H3BRAF
SCHEMBL14730252 0.90 GPR119 (0.37) NTRK1VNN1NR1H2NR1H3BRAF
SCHEMBL14730312 0.90 GPR119 (0.36) NTRK1VNN1NR1H2NR1H3BRAF
SCHEMBL14730327 0.90 GPR119 (0.35) NR1H2NR1H3EIF2AK4MAPTGPR119
SCHEMBL14730167 0.89 GPR119 (0.37) NR1H2NR1H3GPR119
SCHEMBL14730173 0.87 PDK2 (0.34) NR1H2NR1H3BRAFEIF2AK4CCR5
SCHEMBL14730207 0.87 NTRK1 (0.34) NTRK1VNN1NR1H2NR1H3BRAF
SCHEMBL14730206 0.87 GPR119 (0.36) NR1H2NR1H3GPR119
SCHEMBL14730325 0.86 NTRK1 (0.33) NTRK1NR1H2NR1H3EIF2AK4CCR5
SCHEMBL14730216 0.86 GPR119 (0.33) NTRK1VNN1NR1H2NR1H3BRAF

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2013026587-A1 1,4 DISUBSTITUTED PYRROLIDINE - 3 - YL -AMINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF METABOLIC DISORDERS PROSIDION LIMITED (GB) 2013-02-28 WO disclosed